CBR Pharma Engages DelMorgan & Co. to Pursue $24 Million Capital Raise to Fund Cannabinoid API Production

_{For Release - Sunday 17th September 2023}

CBR Pharma Ltd., a startup specializing in the production of GMP- certified cannabinoid active pharmaceutical ingredients (APIs), is pleased to announce its engagement of DelMorgan & Co., a global investment banking firm with a strong track record in the pharmaceutical sector.
‍

DelMorgan & Co. has been engaged to provide world-class financial advisory services to CBR Pharma, focusing initially on a capital raise of $24 million.
‍

"Our engagement of DelMorgan & Co. aligns perfectly with our mission to excel in the production of compliant cannabinoid APIs" stated Cormac MacGowan, CEO of CBR Pharma Ltd.

^{Cormac MacGowan - Founder & CEO of CBR Pharma}

CEO Cormac MacGowan brings a diverse range of experience in business design, leadership, and investor relations. Complementing his leadership are key team members with decades of experience in pharmaceutical manufacturing and quality control. Their specialized expertise is instrumental in navigating the complex regulatory landscape and ensuring consistent, high- quality production. Together, they position the company to leverage the financial prowess and strategic intelligence of DelMorgan & Co.
‍

"Their expertise will be a crucial asset in realizing our ambitious objectives" added MacGowan.

^{Cormac MacGowan - Founder & CEO of CBR Pharma}

The company is starting with a prudent level of production, designed for scalability and prepared to adapt to future market opportunities.
‍

CBR Pharma is focused on the production of GMP-certified APIs for use in finished medicines that have received or are seeking regulatory approval. The company's expertise lies in understanding the industrial processes and meeting the regulatory obligations required in the pharmaceutical sector.
‍

Headquartered in Santa Monica, California, DelMorgan & Co. (www.delmorganco.com) is an internationally recognized investment bank and financial advisor. With over three decades of experience and over $300 billion in successfully completed transactions, the professionals at DelMorgan & Co. provide world-class financial advice and assistance to companies, institutions, governments and individuals around the world.
‍

CBR Pharma Ltd.
Cormac MacGowan - CEO of CBR Pharma Ltd
Email: info@cbrpharma.com Phone: +353 (85) 172 8277

DelMorgan & Co.
Rob Delgado/Neil Morganbesser
Email: inquiries@delmorganco.com Phone: 310-319-2000

‍
‍

• Industry Expertise: With a team of experienced professionals, we possess in-depth knowledge of cannabinoid manufacturing and pharmaceutical development. Our expertise in navigating the complexities of GMP for API standards enables us to deliver high-quality cannabinoids that meet the stringent requirements of our pharmaceutical partners.
• Investor Opportunities: CBR Pharma welcomes interested investors who share our vision of becoming a global leading supplier of GMP API Cannabinoids. While we strive to create investment opportunities and collaborations, please note that the information provided represents our current plans and is subject to change.
• Pharmaceutical Partnerships: We invite pharmaceutical companies interested in sourcing high-quality cannabinoid products for their FDA/EMA approved medicines to consider partnering with CBR Pharma. Our commitment to meeting the GMP for API standards ensures that our cannabinoids meet the rigorous requirements for active pharmaceutical ingredients.

Choose CBR Pharma for our dedication to GMP API Cannabinoids, our commitment to meeting the GMP
for API standards in our future state-of-the-art facility, regulatory compliance, industry expertise, investor
opportunities, and pharmaceutical partnerships.

_{[1] Disclaimer: This information is presented as part of our plans and should not be construed as a guarantee. The content provided is subject to change, and it does not constitute an offer or solicitation to sell securities or an invitation to offer to buy or subscribe for any securities. The information contained herein is confidential and should be treated as such. Any projections or forward-looking statements are based on certain assumptions and may not reflect actual results. The Company does not undertake any obligation to update the information herein to reflect actual results or changes in assumptions or other factors. The accuracy of economic and market information obtained from published sources or prepared by other parties is not guaranteed. The Company has no operating history, and past performance by the principals is not indicative of future performance by the Company.}